10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow

Regulatory Philosophy: Master Recipe vs. Production Execution

In sterile compounding quality management, documentation provides the legal, clinical, and operational bridge ensuring that every compounded sterile preparation (CSP) reliably meets its identity, purity, potency, and sterility specifications. Under USP General Chapter <797> (2023 Revision), sterile compounding documentation is built upon a strict two-tiered structural hierarchy:

1. The Master Formulation Record (MFR): The permanent, validated "master recipe" and procedural protocol detailing how a specific CSP must be compounded.
2. The Compounding Record (CR): The individualized, lot-specific batch execution logbook documenting what actually occurred during a specific compounding event.

Historical root-cause investigations into catastrophic compounding tragedies (most notably the 2012 New England Compounding Center meningitis outbreak) revealed that improper documentation, unvalidated recipe alterations, and absent component traceability were central contributing factors. Consequently, current USP standards enforce rigorous boundaries governing when an MFR is mandated and what data elements must be captured on the CR.

When is a Master Formulation Record (MFR) Mandated?

Under USP <797>, an MFR is not required for every single compound, but it is strictly required under two primary conditions:

1. Batching for Multiple Patients: Whenever a CSP is prepared for more than one patient in a single compounding session.
2. Nonsterile Starting Components: Whenever a CSP is compounded from one or more nonsterile raw ingredients, bulk active pharmaceutical ingredients (APIs), or nonsterile components—even if the preparation is prepared for an individual, single patient!

Mandated Components of the Master Formulation Record (MFR)

An MFR serves as the overarching standard operating procedure for a formulation. It is written and approved before any batch is made, and any change must be approved and documented under the facility's SOPs. USP <797> Box 9 lists the minimum contents:

1. Name, strength or activity, and dosage form of the CSP (e.g., Morphine Sulfate 50 mg/mL Preservative-Free Epidural Injection).
2. Identities and amounts of all ingredients, plus relevant characteristics of components such as particle size, salt form, purity grade and solubility.
3. Type and size of the container-closure system(s) (e.g., 100 mL EVA bag or Type I glass vial with 20 mm chlorobutyl stopper).
4. Complete instructions for preparing the CSP: equipment, supplies, a description of the compounding steps, and any special precautions.
5. Physical description of the final CSP (appearance, color, clarity).
6. BUD and storage requirements.
7. Reference source to support the stability of the CSP.
8. Quality control (QC) procedures, such as pH testing and filter integrity testing.
9. Other information needed to describe the process and ensure repeatability, such as pH or tonicity adjustment and the sterilization method (steam, dry heat, irradiation or filtration).

Many facilities also put the required PEC and SEC, labeling templates and acceptance limits into the MFR. That is good practice, but these are not separate Box 9 items. Keep the two apart on the exam: USP's list is the minimum.

The Compounding Record (CR): Real-Time Batch Documentation

While the MFR describes how the product must be made, the Compounding Record (CR) documents the actual execution of a specific compounding event. A unique CR must be created for every single compounded batch or individual preparation. It functions as the permanent legal and clinical audit trail verifying that personnel adhered strictly to the MFR.

Mandated Components of the Compounding Record (CR)

USP <797> Box 10 sets the minimum CR contents: name, strength and dosage form; date and time of preparation; an internal identification number; a way to identify the people who compounded and verified the CSP; each component's name, weight or volume and strength; vendor, lot number and expiration date for each component when the CSP is for more than one patient or has nonsterile ingredients; total quantity compounded; final yield; BUD and storage; and QC results. If applicable, it also includes the MFR reference and the calculations. A typical batch CR expands on this:

• MFR Reference: The exact name, unique identification code, and revision version number of the MFR utilized.
• Internal Lot or Tracking Number: A unique, internally generated identification number assigned to that specific batch (e.g., LOT-20260929-004).
• Component Traceability: For every raw chemical, API, commercial drug vial, diluent, filter, and container-closure used:
  • Exact component name
  • Manufacturer / supplier / vendor name
  • Manufacturer commercial lot number
  • Manufacturer expiration date
  • Certificate of Analysis (CoA) reference (for nonsterile bulk substances)
• Actual Measured Quantities: Exact raw tare weights, gross weights, net component weights, and liquid volumes measured during preparation (often evidenced by attached analytical balance printouts).
• Calculations and Verifications: The calculations used to determine and verify quantities and concentrations (required if applicable). Independent double checks are facility practice.
• Personnel Identification: USP requires a method to identify the people involved and those who verify the final CSP. Facilities typically record names or electronic credentials of:
  • The individual(s) who physically prepared the CSP (technician or pharmacist)
  • The pharmacist who performed in-process component checks
  • The supervising pharmacist who verified and released the finished batch
• Date and Time: The date and time of preparation.
• Assigned BUD and Storage: The calculated beyond-use date and storage specifications matching the MFR.
• Quality Control Results: Empirical records of all release checks performed on that batch:
  • Visual inspection results (clarity, container integrity, lack of particulates)
  • Measured pH value
  • Actual batch volume or unit count yield
  • Post-filtration filter integrity test results (e.g., measured bubble point: 48 psi; passes manufacturer minimum specification of 45 psi)
  • Analytical assay, sterility, or endotoxin results (if applicable)
• Total Quantity Prepared: The actual number of units compounded (e.g., 100 minibags compounded: 98 units placed into inventory, 2 units sacrificed for destruct quality control testing).
• Label Reconciliation (practice): Checking that the number of printed labels matches the units prepared, and destroying unused labels, prevents mislabeling.

Comparative Matrix: MFR vs. CR

Audit Trails, Discrepancies & Regulatory Archival

USP <797> requires records to be legible, protected from loss, readily retrievable, and compliant with the record-keeping laws of the jurisdiction. The state board's retention period is what inspectors enforce for 503A pharmacies; for comparison, USP <795> keeps nonsterile compounding records for at least 3 years after preparation. Outsourcing facilities follow CGMP, which requires batch records to be kept at least 1 year after the batch's expiration date (21 CFR 211.180). Records may be archived in paper format or in electronic systems that comply with immutable audit trail standards (e.g., role-based access, date/time stamping, and electronic signature integrity).

Handling Discrepancies and Out-of-Specification (OOS) Results

If any parameter recorded on the CR fails to meet the acceptance criteria established in the MFR (e.g., the measured pH is outside the target window, a filter bubble point pressure falls below the validated threshold, or the yield falls outside the tolerance set in the MFR), the batch cannot be released as it is.